Your browser doesn't support javascript.
loading
In vivo imaging of tau pathology using multi-parametric quantitative MRI.
Wells, J A; O'Callaghan, J M; Holmes, H E; Powell, N M; Johnson, R A; Siow, B; Torrealdea, F; Ismail, O; Walker-Samuel, S; Golay, X; Rega, M; Richardson, S; Modat, M; Cardoso, M J; Ourselin, S; Schwarz, A J; Ahmed, Z; Murray, T K; O'Neill, M J; Collins, E C; Colgan, N; Lythgoe, M F.
Afiliação
  • Wells JA; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK. Electronic address: jack.wells@ucl.ac.uk.
  • O'Callaghan JM; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Holmes HE; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Powell NM; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK; Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK.
  • Johnson RA; Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
  • Siow B; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Torrealdea F; Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK.
  • Ismail O; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Walker-Samuel S; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Golay X; Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK.
  • Rega M; Brain Repair & Rehabilitation, Institute of Neurology, University College London, UK.
  • Richardson S; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Modat M; Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK.
  • Cardoso MJ; Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK.
  • Ourselin S; Translational Imaging Group, Centre for Medical Imaging Computing, University College London, UK.
  • Schwarz AJ; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
  • Ahmed Z; Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
  • Murray TK; Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
  • O'Neill MJ; Eli Lilly & Co. Ltd, Erl Wood Manor, Windlesham, Surrey GU20 6PH, UK.
  • Collins EC; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
  • Colgan N; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
  • Lythgoe MF; UCL Centre for Advanced Biomedical Imaging, Division of Medicine and Institute of Child Health, University College London, UK.
Neuroimage ; 111: 369-78, 2015 May 01.
Article em En | MEDLINE | ID: mdl-25700953
ABSTRACT
As the number of people diagnosed with Alzheimer's disease (AD) reaches epidemic proportions, there is an urgent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition. Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aberrant accumulation of tau proteins into neurofibrillary tangles (NFTs) are the focus of substantial current interest. Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with animal models that faithfully reflect aspects of the human disease are urgently required. Magnetic resonance imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany AD progression. However the descent into dementia is not defined by macroscopic brain matter loss alone non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for assessing drug efficacy. Here we employ a multi-parametric array of five translatable MRI techniques to characterise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging, diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in the white matter, decreased amide proton transfer and hyperperfusion. We demonstrate that the above markers unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehensive profile of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic intervention.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Proteínas tau / Tauopatias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Neuroimage Assunto da revista: DIAGNOSTICO POR IMAGEM Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imageamento por Ressonância Magnética / Proteínas tau / Tauopatias Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals Idioma: En Revista: Neuroimage Assunto da revista: DIAGNOSTICO POR IMAGEM Ano de publicação: 2015 Tipo de documento: Article